Meeting
2023 ASCO Annual Meeting
A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.
Authors
Lei Xiao
Innovative Cellular Therapeutics Co., Ltd., Rockville, MD
Lei Xiao , Naifei Chen , Chengfei Pu , Lingling Zhao , Ning Li , Chang Wang , Yusheng Huang , Su-xia Luo , Xun Li , Zhenzhou Yang , Ruihong Zhu , Tingting Liang , Yizhuo Wang , Beibei Jia , Dongqi Chen , Zhao Wu , Yongping Song , Victor Lu , Jiuwei Cui , Jun Bie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
ChiCTR2000040645
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3547)
DOI
10.1200/JCO.2023.41.16_suppl.3547
Abstract #
3547
Poster Bd #
247
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer.
First Author: Jiuwei Cui
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2022 ASCO Annual Meeting
KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
First Author: Loretta J. Nastoupil